NCT04006522

89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Recruiting now Phase 2 Last updated 20 February 2026

What this trial tests

Phase 2 trial testing 89Zr-DFO-Atezolizumab in Renal Cell Carcinoma in 55 participants. Currently enrolling.

Timeline

2 October 2019

Primary endpoint
7 October 2025

31 December 2026

Quick facts

Lead sponsor	James Brugarolas
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	55
Start date	2 October 2019
Primary completion	7 October 2025
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

• 89Zr-DFO-Atezolizumab — full drug profile →
• Positron Emission Tomography/Computed Tomography

Conditions studied

• Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →

Sponsor

James Brugarolas — full company profile →

Who can join

18 and older, any sex, with Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC). This open label, nontherapeutic trial will test the correlation of 89Zr-DFO-Atezolizumab immunoPET/CT with programmed death-ligand 1 (PD-L1) expression and the response to immune checkpoint inhibitor therapy in patients with RCC. There will be two cohorts, one made up of patients with localized RCC who will undergo 89Zr-DFO-Atezolizumab PET/CT prior to nephrectomy and a second cohort of patients with metastatic RCC who will undergo 89Zr-DFO-Atezolizumab PET/CT prior to treatment with an immune checkpoint inhibitor.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Radiopharmaceuticals and their applications in medicine.
   Zhang S, Wang X, Gao X, Chen X, et al · · 2025 · cited 113× · PMID 39747850 · DOI 10.1038/s41392-024-02041-6
2. Radiolabeled Antibodies for Cancer Imaging and Therapy.
   Parakh S, Lee ST, Gan HK, Scott AM. · · 2022 · cited 78× · PMID 35326605 · DOI 10.3390/cancers14061454
3. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the "all-around warrior" in immunotherapy.
   Liu Q, Guan Y, Li S. · · 2024 · cited 50× · PMID 39223527 · DOI 10.1186/s12943-024-02095-8
4. A renal cell carcinoma tumorgraft platform to advance precision medicine.
   Elias R, Tcheuyap VT, Kaushik AK, Singla N, et al · · 2021 · cited 47× · PMID 34818533 · DOI 10.1016/j.celrep.2021.110055
5. Nanobodies as non-invasive imaging tools.
   Rashidian M, Ploegh H. · · 2020 · cited 35× · PMID 35754459 · DOI 10.1016/j.iotech.2020.07.001
6. Noninvasive Imaging of Cancer Immunotherapy.
   Abousaway O, Rakhshandehroo T, Van den Abbeele AD, Kircher MF, et al · · 2021 · cited 27× · PMID 33391977 · DOI 10.7150/ntno.50860
7. Molecular Immune Targeted Imaging of Tumor Microenvironment.
   Rakhshandehroo T, Smith BR, Glockner HJ, Rashidian M, et al · · 2022 · cited 19× · PMID 35223381 · DOI 10.7150/ntno.66556
8. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.
   Mulgaonkar A, Elias R, Woolford L, Guan B, et al · · 2022 · cited 18× · PMID 36074149 · DOI 10.1158/1078-0432.ccr-22-1547